Connor, Clark & Lunn Investment Management Ltd. Royalty Pharma PLC Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Royalty Pharma PLC stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 17,366 shares of RPRX stock, worth $650,877. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,366Holding current value
$650,877% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding RPRX
# of Institutions
503Shares Held
307MCall Options Held
1.99MPut Options Held
384K-
Morgan Stanley New York, NY46.6MShares$1.75 Billion0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA36.4MShares$1.36 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY23MShares$863 Million0.01% of portfolio
-
Capital International Investors Los Angeles, CA21.9MShares$820 Million0.14% of portfolio
-
Baillie Gifford & CO18MShares$675 Million0.51% of portfolio
About Royalty Pharma plc
- Ticker RPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 437,139,008
- Market Cap $16.4B
- Description
- Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...